1. Home
  2. PGEN vs JSPR Comparison

PGEN vs JSPR Comparison

Compare PGEN & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PGEN
  • JSPR
  • Stock Information
  • Founded
  • PGEN 1998
  • JSPR 2018
  • Country
  • PGEN United States
  • JSPR United States
  • Employees
  • PGEN N/A
  • JSPR N/A
  • Industry
  • PGEN Biotechnology: Pharmaceutical Preparations
  • JSPR Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • PGEN Health Care
  • JSPR Health Care
  • Exchange
  • PGEN Nasdaq
  • JSPR Nasdaq
  • Market Cap
  • PGEN 292.6M
  • JSPR 342.2M
  • IPO Year
  • PGEN N/A
  • JSPR N/A
  • Fundamental
  • Price
  • PGEN $0.91
  • JSPR $25.09
  • Analyst Decision
  • PGEN Buy
  • JSPR Strong Buy
  • Analyst Count
  • PGEN 5
  • JSPR 10
  • Target Price
  • PGEN $7.00
  • JSPR $74.86
  • AVG Volume (30 Days)
  • PGEN 915.1K
  • JSPR 213.6K
  • Earning Date
  • PGEN 11-14-2024
  • JSPR 11-07-2024
  • Dividend Yield
  • PGEN N/A
  • JSPR N/A
  • EPS Growth
  • PGEN N/A
  • JSPR N/A
  • EPS
  • PGEN N/A
  • JSPR N/A
  • Revenue
  • PGEN $3,963,000.00
  • JSPR N/A
  • Revenue This Year
  • PGEN N/A
  • JSPR N/A
  • Revenue Next Year
  • PGEN $426.76
  • JSPR N/A
  • P/E Ratio
  • PGEN N/A
  • JSPR N/A
  • Revenue Growth
  • PGEN N/A
  • JSPR N/A
  • 52 Week Low
  • PGEN $0.77
  • JSPR $4.00
  • 52 Week High
  • PGEN $1.93
  • JSPR $31.01
  • Technical
  • Relative Strength Index (RSI)
  • PGEN 50.79
  • JSPR 67.21
  • Support Level
  • PGEN $0.84
  • JSPR $22.30
  • Resistance Level
  • PGEN $0.97
  • JSPR $23.60
  • Average True Range (ATR)
  • PGEN 0.07
  • JSPR 1.63
  • MACD
  • PGEN 0.01
  • JSPR 0.20
  • Stochastic Oscillator
  • PGEN 64.95
  • JSPR 99.06

About PGEN Precigen Inc.

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

About JSPR Jasper Therapeutics Inc.

Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.

Share on Social Networks: